Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CA5-H82F8 | Human | Biotinylated Human CA125 / MUC16 (13810-14451) Protein, Fc,Avitag™ | ![]() |
![]() ![]() |
|
CA5-H82F4 | Human | Biotinylated Human CA125 / MUC16 Protein, Fc,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
RG-7882 | RG-7882; D-4064A; DMUC-4064A | Phase Ⅰ | Genentech | Ovarian cancer, Pancreatic cancer | Details |
Igovomab | Withdrawn | CIS bio international | Ovarian cancer | Details | |
Oregovomab | MAb-B43.13; B43.13 | Phase Ⅲ | Paladin Pharma, National Cancer Institute, Quest PharmaTech, University of Nebraska Medical Center | Ovarian cancer, Pancreatic cancer | Details |
Sofituzumab vedotin | RG-7458; DMUC-5754A | Phase Ⅰ | Genentech | Fallopian tube cancer, Peritoneum cancer, Ovarian cancer, Pancreatic cancer | Details |
JCAR-020 | JCAR-020 | Phase Ⅰ | Memorial Sloan-Kettering Cancer Center, Juno Therapeutics | Ovarian cancer | Details |
This web search service is supported by Google Inc.